DSEN Abstract
Utility of social media and crowd-intelligence data for pharmacovigilance: A scoping review

This research was funded by the Drug Safety and Effectiveness Network (DSEN) and conducted by the following investigators: Andrea C. Tricco, Wasifa Zarin, Erin Lillie, Serena Jeblee, Rachel Warren, Paul A. Khan, Reid Robson, Ba’ Pham, Graeme Hirst, Sharon E. Straus. The statements made herein are those of the stated authors, who are independent researchers.

Summary and Key Messages

  •  We aimed to characterize the literature on the use of social media data sources for drug safety surveillance. Current evidence suggests that social media data sources have the potential to supplement data from regulatory agency databases, are able to capture less frequently reported adverse events (AEs), and can identify AEs earlier than official alerts. However, our findings suggest that the development of such a platform is in its infancy.
  • We conducted this scoping review to inform members of Health Canada in planning an evaluation study on the utility of social media for detecting health product adverse events. This review may inform them on the feasibility of a social media listening platform for drug safety surveillance in Canada.

For more information, please contact Dr. Andrea Tricco: Andrea.Tricco@unityhealth.to.

What is the issue?

What was the aim of the study?

How was the study conducted?

What did the study find?


Link to publications: Tricco et al, 2018.

Date modified: